Muthu V. Kumaran

Professor

UAMS
Last publication 2025 Last refreshed 2026-05-16

faculty

26 h-index 297 pubs 2,504 cited

Research Areas

Links

ORCID

OverviewAI-generated summary

Muthu V. Kumaran's research focuses on the efficacy and outcomes of CAR-T cell therapy, specifically brexucabtagene autoleucel, for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R ALL). His work has investigated patient populations including those aged 60 and above, and has examined factors influencing treatment success, such as NGS MRD negativity and KMT2Ar mutations. Kumaran's publications also explore the impact of social determinants of health on CAR-T therapy outcomes and the predictive value of CAR and Hematotox scores for toxicity and patient prognosis within the ROCCA Consortium.

Beyond hematologic malignancies, Kumaran has also published on pulmonary conditions, including outcomes of bronchoscopic lung volume reduction with endobronchial valves for emphysema and a rare case of isolated systemic arterial supply to the upper lobe of the left lung. His scholarship metrics include an h-index of 2 and 10 total publications.

Metrics

  • h-index: 26
  • Publications: 297
  • Citations: 2,504

Selected Publications

  • The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (2025)
    1 citation DOI OpenAlex
  • Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)
    4 citations DOI OpenAlex
  • Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy (2025)
    8 citations DOI OpenAlex
  • Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)
    3 citations DOI OpenAlex
  • Impact of Response to Bridging Therapy on Outcomes of CAR-T Therapy in Relapsed/Refractory DLBCL: A Single Center Retrospective Analysis (2024)
    DOI OpenAlex
  • Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above (2024)
    3 citations DOI OpenAlex
  • NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival (2024)
    2 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

79 Collaborators 51 Institutions 1 Country

Top Collaborators

Similar Researchers

Based on overlapping research topics

Kathleen E. McGinness University of Arkansas for Medical Sciences
CAR-T cell therapy research Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology
Good match 4 shared topics
Munawwar Hussain University of Arkansas for Medical Sciences
CAR-T cell therapy research Health disparities and outcomes Pharmacological Effects and Toxicity Studies
Good match 4 shared topics
Brett Daughdrill University of Arkansas for Medical Sciences
CAR-T cell therapy research Health disparities and outcomes Cancer Treatment and Pharmacology
Good match 4 shared topics
Matthew D. Thompson University of Arkansas for Medical Sciences
Health disparities and outcomes Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology
Good match 4 shared topics
Lauren Elizabeth Appell University of Arkansas for Medical Sciences
CAR-T cell therapy research Acute Lymphoblastic Leukemia research Cancer Treatment and Pharmacology
Good match 3 shared topics
Kaitlynn Butler University of Arkansas for Medical Sciences
Acute Lymphoblastic Leukemia research Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology
Good match 4 shared topics